QIMR Berghofer

Artesunate-mefloquine versus chloroquine for treatment of uncomplicated Plasmodium knowlesi malaria in Malaysia (ACT KNOW): an open-label, randomised controlled trial


Background The zoonotic parasite Plasmodium knowlesi has become the most common cause of human malaria in Malaysia and is present throughout much of southeast Asia. No randomised controlled trials have been done to identify the optimum treatment for this emerging infection. We aimed to compare artesunate-mefloquine with chloroquine to define the optimum treatment for uncomplicated P knowlesi malaria in adults and children.

Authors Grigg, Matthew J.; William, Timothy; Menon, Jayaram; Dhanaraj, Prabakaran; Barber, Bridget E.; Wilkes, Christopher S.; von Seidlein, Lorenz; Rajahram, Giri S.; Pasay, Cielo; McCarthy, James S.; Price, R. N.; Anstey, Nicholas M.; Yeo, Tsin W.
Pages 180-188
Volume 16
Date 1/02/2016
Grant ID
Funding Body Malaysian Ministry of Health
URL http://www.ncbi.nlm.nih.gov/pubmed/?term=10.1016/S1473-3099(15)00415-6